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Abstract Fragment-based drug discovery (FBDD) has be-
come a new strategy for drug discovery where lead com-
pounds are evolved from small molecules. These fragments
form low affinity interactions (dissociation constant (KD)0
mM−μM) with protein targets, which require fragment
screening methods of sufficient sensitivity. Weak affinity
chromatography (WAC) is a promising new technology for
fragment screening based on selective retention of frag-
ments by a drug target. Kinases are a major pharmaceutical
target, and FBDD has been successfully applied to several
of these targets. In this work, we have demonstrated the
potential to use WAC in combination with mass spectrom-
etry (MS) detection for fragment screening of a kinase target
—cyclin G-associated kinase (GAK). One hundred seventy
fragments were selected for WAC screening by virtual
screening of a commercial fragment library against the
ATP-binding site of five different proteins. GAK protein
was immobilized on a capillary HPLC column, and com-
pound binding was characterized by frontal affinity chroma-
tography. Compounds were screened in sets of 13 or 14, in
combination with MS detection for enhanced throughput.
Seventy-eight fragments (46 %) with KD<200 μM were
detected, including a few highly efficient GAK binders
(KD of 2 μM; ligand efficiency00.51). Of special interest
is that chiral screening by WAC may be possible, as two
stereoisomeric fragments, which both contained one chiral
center, demonstrated twin peaks. This ability, in
combination with the robustness, sensitivity, and simplicity
of WAC makes it a new method for fragment screening of
considerable potential.
Keywords Fragment screening . Fragment-based drug
discovery . Cyclin G-associated kinase . Weak affinity
chromatography
Introduction
During the last 10 years, the fragment-based drug discovery
(FBDD) paradigm, where a lead compound is evolved from
small molecular fragments that bind to a biological target,
has to an increasing extent been implemented both within
academia and the pharmaceutical industry [1–3]. Problems
presented by high-throughput screening (HTS) such as low
hit rates and difficulties in optimizing hits into lead com-
pounds with adequate ADME properties [4] has led to the
use of FBDD either as a complement or replacement to
HTS. It is believed that FBDD enables the development of
inhibitors against difficult targets where HTS has failed [5].
Originally, the concept of FBDD was presented by
Jencks in 1981 [6]. In 1996, Shuker et al. presented the
“SAR-by-NMR” approach where nuclear magnetic reso-
nance (NMR) was used to find two different fragments that
bound to various locations of the binding site of a target
protein. Subsequent linking of the two fragments to each
other resulted in a compound with nanomolar affinity to the
target, demonstrating the concept of FBDD in practice [7].
In 2011, the FDA approved the first drug that had been
developed by FBDD—the oncogenic B-Raf inhibitor Zel-
boraf as a therapy against malignant melanoma [8]. Several
other candidate drugs that have been developed by FBDD
are currently in clinical trials, and many of these are kinase
inhibitors. Kinases are involved in a range of different
biological processes such as signaling, proliferation,
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apoptosis, and differentiation [9]. As kinases have been
related to many different types of pathological states, such
as cardiovascular diseases, cancer, and neurodegenerative
diseases [9, 10], a considerable amount of research is now
devoted to finding drugs that target kinases [11]. FBDD has
proven successful when applied to kinases as drug targets
and numerous examples exist of FBDD projects targeting
kinases, such as PIM [12], PI3K [13], and PDK1 [14]. The
majority of kinase inhibitors target the ATP-binding site
which, due to the conserved nature of this site among
kinases, often leads to difficulties obtaining specificity [11].
However, it has also been proposed that promiscuity of kinase
inhibitors can be beneficial in some instances [15, 16].
As the number of possible combinations of a molecule
increases exponentially with the number of heavy atoms in a
molecule, screening of molecules that are smaller in size
enables coverage of a greater portion of chemical space [4,
17]. As a result, fragment libraries are much smaller than
HTS libraries, consisting of only hundreds to a few thou-
sand compounds [18, 19].
Due to the small size of fragments (<300 Da [20]), frag-
ments form weak although high-quality interactions to the
target with dissociation constants (KD) in the micromolar to
millimolar range [2, 19]. This puts great demands on tech-
nologies used for fragment screening, for example in terms
of sensitivity and throughput. Surface plasmon resonance
(SPR), NMR, X-ray crystallography, and isothermal titra-
tion calorimetry are techniques that are frequently employed
today for fragment screening [19, 21]. Weak affinity chro-
matography (WAC) [22] has in a number of studies been
applied to analytical affinity separations including carbohy-
drate [23, 24] and chiral analyses [25]. In recent studies, it
has also been applied to fragment screening on proteases as
model target proteins [26]. This is a technique which carries
all the inherent properties of HPLC combined with the
selectivity of affinity. Moreover, analysis of sample mix-
tures combined with MS detection further enables high
throughput and sensitivity of detection.
In this study, fragment screening by WAC with MS
detection is demonstrated for the first time against a kinase
target by screening a larger set of substances. The cyclin G-
associated kinase (GAK) was used as a model protein target
for kinase, which also has been suggested as a potential drug
target for Parkinson’s disease [27, 28]. GAK was immobi-
lized on a capillary column for minimal protein consump-
tion, and characterization was performed by frontal affinity
chromatography to assess the number of active sites.
Screening by WAC was preceded by virtual screening of a
3,200-compound commercial fragment library against the
ATP-binding site of five different protein structures. One
hundred seventy fragments with the highest average rank
were subject to fragment screening by WAC. WAC showed
promise as a technology for fragment screening against




A fragment-based library of 3,200 fragments was obtained
from TimTec, Newark, DE. The molecular weights of the
fragments were between 75 and 289 Da. All fragments had a
cLogP, ≤2.5; hydrogen bond acceptors, ≤5; hydrogen bond
donors, ≤3; rotatable bonds, ≤3; and heavy atoms
(nonhydrogen), ≤20. The fragments were dissolved in di-
methyl sulfoxide (DMSO; Sigma Aldrich, St Louis, MO) at
1.5 mM and were further diluted in water to working con-
centrations. Periodic acid, adenosine, sodium cyanoborohy-
dride, and ethanolamine were purchased from Sigma
Aldrich. LB Media was purchased from Novagen (Darm-
stadt, Germany).
Production of GAK
DNA (residues 20–347) of human GAK was PCR amplified
from synthetic DNA and inserted into vector pNIC28-Bsa4
(GI 124015065) [29] by ligation-independent cloning. The
plasmid DNAwas transformed into Escherichia coli Rosetta
(DE3) for protein expression. From an overnight culture
grown in LB (Miller, Novagen) media containing 50 μg/
mL kanamycin and 34 μg/mL chloramphenicol, 6×10 mL
were used to inoculate 6×1 L cultures of LB media con-
taining 50 μg/mL kanamycin, in baffled shaker flasks. Cul-
tures were grown at 37 °C until an OD600 of ∼0.7. The
temperature was reduced to 18 °C for 1 h, and the cultures
were then induced with 0.5 mM isopropyl-β-thio galacto-
pyranoside and left shaking overnight. Cells were harvested
by centrifugation.
The cells were resuspended in 50 mM Hepes at pH 7.5,
500 mM sodium chloride, 5 % glycerol, 5 mM imidazole,
and 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) (bind-
ing buffer) and lysed by sonication. Polyethyleneimine was
added to a final concentration of 0.25 %, and the cell debris
and precipitated DNAwere spun down. The supernatant was
passed through a 3-mL nickel-nitriloacetic acid (Ni-NTA)
column, which was washed with binding buffer (25 mL) and
binding buffer containing 25 mM imidazole (25 mL). The
protein was eluted with binding buffer containing 250 mM
imidazole (15 mL). The eluted fraction was concentrated to
4 mL and injected onto an S200 16/60 gel filtration column
(GE Healthcare, Waukesha, WI) in 25 mM Hepes at pH 7.4,
150 mM sodium chloride, 0.5 mM TCEP (GF buffer).
Fractions containing GAK were pooled, and the protein
was digested with tobacco etch virus protease. The sample
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was passed through 2 mL of Ni-NTA, eluting with GF
buffer containing 20 mM imidazole. The sample was con-
centrated to 13 mg/mL and frozen at −80 °C. Typical yield
of purified GAK protein is about 10 mg/L culture media.
Preparation of affinity capillary columns
GAK was thawed on ice and prepared for immobilization by
dialysis 1/10,000 in 0.1 M sodium phosphate buffer at
pH 7.0 in a Slide-A-Lyser® (Pierce, Rockford, IL) at 4 °C.
The buffer was exchanged three times during dialysis of the
protein. The GAK concentration was estimated by absor-
bance readings at 280 nm (NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, Wilmington, DE)).
Immobilization of GAK and ethanolamine was per-
formed in situ on two stainless-steel capillary columns
(100×0.5 mm) packed with spherical silica particles (5 μm
in diameter, 300 Å pore size; Kromasil, EKA Chemicals,
Bohus, Sweden) which had been silanized into diol-
substituted silica according to standard procedures. Immo-
bilization was performed on an Agilent 1200 HPLC system
(Agilent Technologies, Waldbronn, Germany) by reductive
amination of mainly lysine side chains of the protein and
aldehyde groups of the silica surface essentially as described
earlier [26]. The diol-silica column was rinsed with water
(20 column volumes) (immobilization of ethanolamine) or
was rinsed with isopropanol (20 column volumes) and then
with water (20 column volumes; immobilization of GAK).
For immobilization of GAK and ethanolamine, the diol-
silica columns were oxidized into aldehyde-silica by 10×
40-μL injections of 0.13 g/mL periodic acid at a flow rate of
20 μL/min for 2 min. The flow rate was then stopped for 11
(GAK) or 20 min (ethanolamine) between injections. The
total reaction time was 2 (GAK) or 3.3 h (ethanolamine),
and it was performed at 12 (GAK) or 22 °C (ethanolamine).
The column was then rinsed with water and with 0.1 M
sodium phosphate buffer at pH 7.0 (>20 column volumes).
For the coupling procedure of GAK, 9×40-μL injections of
GAK (2.24 mg/mL) and sodium cyanoborohydride (9 mg/
mL) and 1×40-μL injection of sodium cyanoborohydride
(9 mg/mL) were performed at a flow rate of 20 μL/min for
2 min. The flow was stopped for 2 h between injections. The
total reaction time was 20 h, and it was performed at 12 °C.
Remaining aldehyde-silica groups present on the column
were encapsulated by ethanolamine. This was achieved by
6×40-μL injections of ethanolamine (6.15 mg/mL) and
sodium cyanoborohydride (9 mg/mL) dissolved in 0.1 M
sodium phosphate buffer at pH 7.0 at a flow rate of 20 μL/
min for 2 min. The flow was stopped for 1 h between
injections. The reaction was performed at 12 °C and the
total reaction time was 6 h. For immobilization of ethanol-
amine as a reference column, 10×20-μL injections of etha-
nolamine (6.15 mg/mL) and sodium cyanoborohydride
(9 mg/mL) dissolved in 0.1 M sodium phosphate buffer at
pH 7.0 were performed with a flow rate of 20 μL/min for
1 min. The flow was stopped for 75 min between injections.
The total reaction time was 12.5 h and it was performed at 12 °
C. Both columns were rinsed with 0.1 M sodium phosphate at
pH 7.0 (>20 column volumes). The eluate (including wash-
ings) from the immobilization of GAK was collected and the
yield was determined indirectly from the absorbance at
280 nm of the eluate and applied GAK sample.
Selection of fragments for screening
All calculations were performed using the Schrödinger Suite
2010 (Portland, OR) and with default settings. Five 3D
structures of proteins with an ATP-binding site to which a
ligand was docked was downloaded from the protein data
bank (PDB): Mammalian STE20-like protein kinase 3
(MST3; PDB ID 3CKX), heat shock protein 90 (Hsp90;
PDB ID 2XDK), c-Jun N-terminal kinase 3 (JNK3; PDB
ID 3G90), protein kinase A (PKA; PDB ID 1Q8T), and
vascular endothelial growth factor (VEGFR; PDB ID
3BE2). The protein 3D structures were prepared in the
Protein Preparation Wizard. Any missing side chains in the
structures were predicted by Prime (Prime version 2.2.108).
The water present in the structures was deleted and a recep-
tor grid was prepared of the ATP-binding site. The 3,200
structures of the fragments were prepared by LigPrep (Lig-
prep version 2.4.107) at pH 7.4±2.0 using the ionizer and a
maximum of 32 stereoisomers per ligand. LigPrep generated
5,636 3D structures with variations in, e.g., tautomeric and
ionic form, which were docked flexibly in standard
precision-mode in Glide (Glide version 5.6.107) to the gen-
erated receptor grid of each of the five-protein 3D structures.
The obtained Glide gscores, which is related to the affin-
ity of a fragment to a protein, were used to rank the 3,200
fragments internally with regard to each of the five-protein
3D structures. For each fragment, the average rank with
regard to all five-protein 3D structures was calculated and
the 170 fragments with the highest average rank were se-
lected for further studies.
Column characterization by frontal affinity chromatography
Frontal affinity chromatography was performed essentially
as described by Kasai et al. [31]. An Agilent 1200 HPLC
system equipped with a diode array multiple wavelength
detector was used for the frontal analysis. As mobile phase,
20 mM ammonium acetate at pH 6.8 was used. The flow
rate was 18 μL/min, and the column temperature was 22 °C.
Adenosine was dissolved in the mobile phase and injected
onto the GAK capillary column at 100 μL at concentrations
of 0.025, 0.050, 0.100, 0.200, 0.300, 0.400, 0.500, and
0.750 mM. The breakthrough curve was monitored by UV
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at 214 nm. The void time of the column was determined
with DMSO (0.1 % in water) by an injection volume of
0.4 μL. Chromatograms were analyzed by the Agilent
ChemStation version B.04.01 chromatography data system,
and the front time was assessed from the local maximum of
the first derivative of the front curve. The volume for col-
umn saturation V´R was calculated by adjusting for the void
volume of the column.
The number of moles of adenosine required for saturation
of all active sites present on the column was calculated from
V´R and the concentration of adenosine for each injection.
These values were plotted against the concentrations of
adenosine in each injection in order to generate a one-site
total binding hyperbola using GraphPad Prism 5.0c (San
Diego, CA). Here, the contribution from nonspecific bind-
ing is defined as a linear relation between analyte concen-
tration and amount bound. By nonlinear regression analysis,
the number of binding sites on the column (Btot) and the KD
of adenosine to GAK were determined (Eq. 1).
V
0
R adenosineð Þ ¼
Btot  adenosineð Þ
KD þ adenosineð Þ ð1Þ
Zonal affinity chromatography screening of the fragment
library
Fragment screening was performed on an Agilent 1200
series capillary HPLC system equipped with a single quad-
ropole mass spectrometry (MS) detector. On MS detection,
fragments were ionized by electrospray at atmospheric pres-
sure in positive and negative mode alternatively. Drying
nitrogen gas flow was 7 L/min at 350 °C. The nebulizer
pressure was 15 psig, and the capillary voltage was 3,000 V
in positive mode and −2,500 V in negative mode. MS signal
acquisition was set at selected ion monitoring (SIM) mode
on sample target masses. Both the [M+1]+ and the [M−1]−
ion was monitored for each analyte. The fragmentor was set
to 100 V in positive SIM mode and to 173 V in negative
SIM mode. Retention times were based on peak apexes of
the extracted ion chromatogram (EIC). Chromatograms
were analyzed with the Agilent ChemStation version
B.04.01 chromatography data system.
Ammonium acetate buffer (20 mM) at pH 6.8 was used
as mobile phase throughout the studies and the analyses
were performed isocratically. Fragments were analyzed in
mixtures with 13 or 14 fragments in each mixture, resulting
in 13 different mixtures. The concentration was 5.0 or
5.3 μM of each fragment and a DMSO concentration of
4.6 or 4.7 %. Adenosine was also present as a control in
each mixture at an equal concentration as the other analytes
present in the mixture. The retention time of adenosine was
monitored continuously and was used as a measure of the
activity of the column. Each mixture was analyzed in dupli-
cate samples on both the GAK column and the reference
(ethanolamine) column. Screening was performed with an
injection volume of 0.4 μL and a flow rate of 20 μL/min.
The column temperature was set to 22 °C.
Data analysis
The KD of each fragment with regard to binding to GAK






where F is the flow rate during screening and t´R, specific is
the adjusted retention time on the GAK column (t’R, GAK),









The adjusted retention times were calculated by subtrac-
tion of the retention time of the void marker DMSO from the
retention times of the analytes. Equation 2 is valid under a
linear isotherm, i.e. when the concentration of the analyte
during analysis on the column is much smaller than the
analyte’s KD value.
Results and discussion
Selection of fragments by virtual screening
Through virtual screening by Glide, 170 fragments were
selected from a fragment based library of 3,200 substances
on the basis of their average internal rank towards the ATP-
binding site of five crystal structures of four kinases of
different types and one chaperone (MST3, Hsp90, JNK3,
PKA, and VEGFR). The structures of these randomly se-
lected proteins with an ATP-binding site were used for
virtual screening as there were no crystal structures available
for GAK with a docked inhibitor that could be used for
ligand docking by Glide. The object was to find fragments
with affinity to the ATP-binding site, which would produce
a set of fragments that were likely to bind to GAK or other
kinases due to the conserved nature of the ATP-binding site.
The object with ligand docking to more than one-protein 3D
structure was to overcome inherent limitations of the com-
putational modeling method, as well as to minor flaws that
may be present in the individual crystal structures.
As water present in the protein crystal structures was
deleted prior to virtual screening, ligands that use waters
to form interactions with the ATP-binding site may have
been missed. In addition, as the virtual screening was
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performed using one single conformation of each protein
structure, ligands that utilize the inherent plasticity of the
kinase for their binding may have been excluded. The mo-
lecular weights of the 170 selected substances were between
147 and 284 Da. The fragments contained ≤20 heavy
(nonhydrogen) atoms, ≤3 hydrogen bond donors, and ≤5
hydrogen bond acceptors and had a cLogP between −1.87
and 2.52.
Production and characterization of GAK capillary column
GAK was immobilized onto a diol-silanized silica capillary
column to prevent nonspecific interactions with the naked
silica surface and to introduce functional groups for protein
coupling. The diol silica was oxidized into aldehyde silica
and GAK was immobilized by reductive amination
(0.78 mg (20.8 nmol); 39.8 mg/mL) at a high coupling yield
(90 %). The GAK column was characterized by frontal
affinity chromatography and the number of active enzyme
sites on the capillary column was determined to be 4.6±
0.7 nmol (R200.988). Thus, the ratio of active sites versus
protein content on the column was 22 %. This value is
typically lower than was experienced in previous studies
with other ligands [23, 26]. The reason for this may be a
decrease in kinase activity during storage prior to immobi-
lization or inactivation by coupling to lysine residues pres-
ent in the ATP-binding site of GAK. However, the
concentration of active sites in the capillary column
(0.23 mM) still makes it theoretically possible to study weak
binding in the low millimolar range. By miniaturization of
column size into capillary columns, consumption of target
protein was well below 1 mg which could be further mini-
mized by an order of magnitude by going into chip format or
shorter capillary columns.
Fragment screening by zonal affinity chromatography
Performance of screening
Figure 1 demonstrates typical chromatograms from analysis
of one mixture of fragments on the GAK column with MS
detection, both the total ion chromatograms (TICs) of SIM-
positive and SIM-negative mode, and EICs for individual
analytes. Adenosine was present in each mixture during
analysis. The KD value for adenosine, as measured by zonal
chromatography (41 μM), was in good agreement with the
KD obtained from frontal affinity chromatography (63 μM).
There was no trend towards shorter retention times of aden-
osine throughout the screening study (a few weeks) indicat-
ing no loss of activity of the GAK column. Out of the 170
selected fragments that were screened by WAC, 145 (85 %)
were detected by MS during analysis on the GAK column
and 141 (83 %) on the reference column. One hundred forty
(82 %) of the fragments were detected on both columns. The
distribution in estimated KD values for these fragments is
shown in Fig. 2. For 78 (46 %) of the screened fragments,
the estimated KD was 200 μM or lower, which represents a
difference in retention time between the GAK column and the
reference column of 1× the void time of the GAK column
(1.13 min; Eq. 2). This number constitutes 2.4 % of the 3,200
compounds in the original Timtec library. The high number of
fragment hits of relatively high affinity indicates that the
selection of fragments for screening that was performed in
silico was successful. A number of false positives may how-
ever be included as fragments binding to parts of the protein
other than the ATP site would also have been detected.
In Fig. 3, some of the best hits from screening of the 170
fragments towards GAK are presented. Fragment ST014664
and ST034758 were the highest ranked hits with adjusted
retention times of 117 and 108 min on the GAK column and
1.14 and 7.39 min on the ethanolamine column, respective-
ly. Fragment ST059935, which is structurally similar to
ST014664 and ST034758 had an adjusted retention time
of 47 min on the GAK column and consequently a very
high ligand efficiency (0.60). Fragments ST057236 and
ST057640 each contain a chiral center, resulting in the
presence of two enantiomers of each compound which
exhibited different affinities to GAK, as shown by double
peaks in the chromatograms (see discussion below) (Fig. 4).
These two fragments hold together with fragment ST048901
a structural resemblance to the favonoid Quercetin, which
caused an increase of melting temperature (ΔTm) of GAK of
9.4 °C during a thermal shift assay performed as described
in [32]. Fragment ST088036, which constitutes a part of
adenosine, was also identified as one of the highest ranked
fragments and the measured affinity was interestingly higher
than that of adenosine to GAK (Fig. 3).
The use of MS detection enables analysis of mixtures by
WAC, increasing the throughput considerably. However,
screening of a selected library such as the one used in this
study requires relatively long elution times; in these studies
each sample was eluted for 140 min. Thus, analysis of the
170 substances as mixtures of 13 compounds would require
33 h. Throughput could be enhanced by screening of mix-
tures containing more analytes. In this study, the number of
compounds in each mixture was limited due to the fragment
concentration in the original library. Using a library at
higher concentrations or in another organic solvent than
DMSO would enable up to 100 analytes in each mixture
and as a result would lead to significantly higher throughput.
Fragment screening by WAC requires very low sample
concentrations (<0.1 mM), which distinguishes the method
from other methods used in fragment screening, making
issues such as analyte solubility, nonspecific binding and
aggregation less of a problem. Thus, the sample consump-
tion was only 2 pmol of each analyte (one injection).
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Chiral separation
Out of the substances that were selected for screening to-
wards GAK, 11 contained chiral centers. During analysis of
two of these substances, double peaks of equal area were
detected for the same m/z (Fig. 4). Analysis of these sub-
stances as single injections verified that both peaks belong
to the same analyte. Meanwhile, analysis of these com-
pounds on the ethanolamine column only resulted in one
peak. All these results taken together indicate that the frag-
ment existed in a racemic mixture and that the enantiomers
of these two fragments are retarded differently due to dif-
ferent affinities in the micrometer range (see Fig. 3). The
occurrence of only one single peak during analysis of the
remaining chiral fragments can be explained by several
factors: (1) the chiral centers of these fragments are not
important for binding; (2) only one enantiomer is present
in the sample; or (3) the second enantiomer of the racemic
mixture was not detected due to carrying an affinity that was
out of the range of detection of this method.
The ability of WAC to perform a chiral separation and
hence determine affinity constants for individual enan-
tiomers presents a significant advantage for WAC for frag-
ment screening as compared with other technologies for
fragment screening such as SPR.
Mass Spectrometry detection
Some fragments (approximately 15 %) were not detected
during screening in this study. Most of the nondetected
fragments were flavones. No extensive optimization study
of the spray chamber settings was conducted in order to be
able to detect all fragments at the low sample concentration
that was used and the parameters applied were probably not
optimal for all fragments. It cannot be excluded that some of
the fragments were nonionizable and consequently unsuit-
able for MS detection by ESI. Some fragments were
detected on the reference column, but not on the GAK
column. Some of them had structural similarities with other
fragments of rather high affinity, such as the flavones.
Therefore, it may be assumed that the affinity of these frag-
ments was above the range of this screening method. Ana-
lytes with KD<1 μM are not suitable for this method as they
are not eluted within a reasonable time. In addition, their


















Fig. 1 Chromatograms of
fragments of mixture 4. (a) TIC
of SIM-positive mode, (c) TIC
of SIM-negative mode, (b)
EICs of individual analytes in
SIM-positive mode (1,
ST025584; 2, ST055793; 3,
ST090280; 4, ST079160; and 5,
adenosine (reference); 6,
ST059588; and 8, ST082975),
and (d) EICs on individual
analytes in SIM negative mode
(1, ST056929; 2, ST066868; 3,
ST069077; 4, ST059588; and 5,
ST066881). Spikes are artifacts
of the MS detector. Some frag-


























Fig. 2 Distribution of dissociation constants (KD) for fragments as
screened by WAC
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considerable peak broadening. However, highly retarded
fragments may be detectable by forced elution by such
means as changes in temperature, pH, ionic strength or
hydrophobicity of mobile phases. However, such elution
methods have to be compatible with the immobilized pro-
tein, the support material and MS detection.
Analytes eluted in the void volume were generally more
difficult to detect due to signal suppression effects from
DMSO and other analytes competing for surface area of
the electrospray droplets. To reduce these effects, the
amount of DMSO present in the samples had to be kept to
a minimum. In this study, the number of fragments in each
Fig. 3 Quercetin, reference
compound adenosine, and
examples of fragment hits from
screening against GAK
Fig. 4 Structure of fragment
ST057236 and EIC from
analysis on the GAK column
(solid line) and on the reference
column (dotted line). The chiral
center of fragment ST057236 is
indicated by a black circle.
Detection was performed in
SIM negative mode of the [M
−1]− ion m/z 271. The KD
values of the enantiomeres were
estimated to 2.5 and 4.9 μM.
Spikes are artifacts of the MS
detector
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mixture was limited to 14 in order to keep the concentration
of DMSO in each mixture to below 5 %. Using a fragment
library where the original samples are provided at higher
concentrations would enable preparation of mixtures con-
taining a higher number of analytes and consequently higher
throughput, while the lower DMSO concentration in each
mixture would limit the influence of DMSO on MS detec-
tion. As DMSO is not an ideal organic solvent to be used in
combination with MS, a library that is dissolved in another
more volatile solvent would be more suitable for this tech-
nique and enable higher throughput. Nevertheless we have
demonstrated that DMSO, which is commonly used to dis-
solve compound libraries, can be used with this technique.
The use of reference column
For 23 (16 %) of the 140 fragments that were detected
during screening on both columns, the adjusted retention
time on the reference column was longer than on the GAK
column. These fragments were between 0.03 and 2.90 col-
umn volumes longer retarded (0.2–18 min) on the ethanol-
amine column than on the GAK column. On the GAK
column a portion of the column surface is shielded by
immobilized protein, but it is difficult to determine to what
extent this changed the binding to the naked matrix. Esti-
mation of affinity constants is difficult for these fragments
with considerable affinity to the derivatized silica matrix and
they are often regarded as nonhits. For screening of such
troublesome fragments, alternative reference columns could
be used based on other matrices or other surface chemistries.
In theory, the GAK column used in this study could be
used to detect millimolar-binding events, as the affinity
range is dependent on the amount of immobilized active
protein. However, the contribution from nonspecific inter-
actions to the overall retention time on the column could be
considerable in the millimolar affinity range [26]. The cut-
off for accurate KD determination was therefore set to
<200 μM in this study. To determine accurate affinity con-
stants of weaker binding events, a reference column with
immobilized, inactivated, target protein would be preferred.
This could be achieved either by a covalent inhibitor or a
high affinity noncovalent inhibitor present in the mobile
phase [26]. This would also enable identification of frag-
ments binding to the target protein outside the active site(s)
which could be of potential interest for developing allosteric
inhibitors.
Conclusions
This paper presents an alternative method of fragment
screening of kinases by introducing affinity LC/MS. One
hundred seventy fragments, selected by virtual screening of
a 3,200-member fragment library, were subjected to WAC
on a capillary column with the immobilized kinase GAK
where some highly efficient binders were defined. WAC
also enabled resolution of racemic mixtures and determina-
tion of affinity constants for individual enantiomers which
represents a unique benefit of WAC for fragment screening.
Combining MS detection with WAC is highly advantageous
in terms of throughput, identification and detection capabil-
ity which could be further optimized by the use of fragment
libraries especially designed for this technology.
Fragment screening by WAC has now been demonstrated
on a few targets including proteases and kinases and it has
been proven to be labor and time efficient. Furthermore,
screening can be performed using standard HPLC equip-
ment. Very little sample is consumed; only nanograms of
each analyte are required. Low fragment concentrations in
the high μM range are used which minimize problems with
sample solubility and aggregation. Another major benefit is
that only one run with a fragment is required to give an
estimate of its affinity and theoretically of its kinetics. The
use of capillary columns limits protein consumption and
further miniaturization is possible. Gentle immobilization
of a protein in porous gels frequently enhances its stability
and as a result affinity columns can be used for months and
withstand hundreds of injections of sample mixtures.
We conclude that WAC is a complementary method
showing great potential for fragment screening in drug
discovery. The method facilitates detection of weak binding
events in a broad affinity range and could be used as a
primary screening tool where ranking of binders in terms
of affinity constants can be obtained by a single sample
injection. Comparison and correlation of the results to data
from other existing fragment screening techniques such as
NMR and SPR will be the subject of future investigations.
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